Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.
about
Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsyReal life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs.Highights in the history of epilepsy: the last 200 yearsVagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children.Clinical utility of eslicarbazepine: current evidence.Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapyEslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.New developments in the management of partial-onset epilepsy: role of brivaracetam.Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.The long-term safety of antiepileptic drugs.Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.Medical management of refractory epilepsy--practical treatment with novel antiepileptic drugs.Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures.Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.Advances in epilepsy in 2013 for the neurohospitalist.Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy.Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.Sodium Channel Blockers in the Treatment of Epilepsy.Eslicarbazepine acetate for the treatment of partial epilepsy.Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide.Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.Decision analysis of intracranial monitoring in non-lesional epilepsy.[Anticonvulsant add-on therapy with Eslicarbazepine acetate : Results of the EPOS-study in adults in Germany].Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures.Recent and Emerging Anti-seizure Drugs: 2013.Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence.Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study.Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy.Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.A review of the pharmacology and clinical efficacy of brivaracetam.Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment.
P2860
Q26745780-0297AFDF-4DA2-4A3A-90F8-AAB7FF0F4935Q33792513-F3650AFE-D01E-4AFF-ADC7-C58C8F31327CQ34151924-B39D370F-928A-4357-94EE-2235ABD91B20Q34439257-ADBD03C5-78A3-406E-AC5E-1C83AE63BE0AQ35087964-5237DD5F-0CCD-4E82-BA81-6BDE2F0581A5Q35936036-B6BB8994-1023-4577-AB5B-C6511FF9C805Q37680030-7944E252-5648-45E5-B69D-00C382EBDF8CQ37693757-21D2C523-AF99-4930-A5A8-8EC889ED194FQ37694387-FD5F04A3-E83B-4B0E-9A41-2BD88A694F46Q38106856-EA2EAC34-A271-471F-946C-732787D7B935Q38115721-CE68490F-942A-4131-A24A-E115D046A51DQ38176649-048F6529-4F3D-4009-B398-BD99B34C0601Q38223958-ADC8D6C9-D1C4-4D65-B0C9-1E4F1B8AE376Q38367761-2B288232-A273-4F2A-8DD1-7F948F8A0BE5Q38616386-E97FCFEE-EE63-4168-B981-17728F2D162DQ38617833-FBB08DA9-A091-41AB-8827-1060085276E0Q38656011-E610C81F-F9DC-476B-B222-3A1DB04B7A6FQ38775516-6DE791B3-3108-4299-BEAB-DD16E577E4FEQ38826584-B29B28D7-80E3-43F9-8A6A-00FA8CD43EAEQ38904679-39187877-FB54-4F0F-8DCC-879576B872BFQ39094490-41DFA058-7A7B-445D-8C8F-16A2942E01BBQ39116160-C7263743-7A21-45E0-809D-CF8B62F45B31Q39456360-B5F9C7E7-6495-4C3C-B7FD-908A154DB0F5Q39652370-DDED5217-07FC-4A35-AB3F-C54E46952E1EQ40611807-43B17798-7266-4347-8A97-6D29FBEA52BFQ44062629-7F6A8EB2-2948-4DF7-952B-38A6C5060E83Q44168300-CF1FD172-402D-4043-9177-5FAE924819EAQ45961350-290BA6B1-3098-4B2B-A658-3B7E9D7A1D21Q47235722-22ABAEC3-F6D4-4C25-8342-F7A08A0CA9D2Q47797132-8DF11B52-115F-4A3F-9FEC-0DC47B7FDF4DQ48258899-DF89456E-4F52-4291-BB42-C2D2ECCF76F2Q48352462-36F00279-F88B-479F-81FF-0903AEA53CF0Q48424510-C90D533E-37FF-4DDE-91C6-8FA0C3702431Q49700507-B05D2115-A777-488B-ACBB-8CA63A26BBD9Q50075643-5D83AAD6-398D-4B2F-9E33-DB26A3AFC875
P2860
Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Efficacy and safety of eslicar ...... nd phase III clinical studies.
@ast
Efficacy and safety of eslicar ...... nd phase III clinical studies.
@en
Efficacy and safety of eslicar ...... nd phase III clinical studies.
@nl
type
label
Efficacy and safety of eslicar ...... nd phase III clinical studies.
@ast
Efficacy and safety of eslicar ...... nd phase III clinical studies.
@en
Efficacy and safety of eslicar ...... nd phase III clinical studies.
@nl
prefLabel
Efficacy and safety of eslicar ...... nd phase III clinical studies.
@ast
Efficacy and safety of eslicar ...... nd phase III clinical studies.
@en
Efficacy and safety of eslicar ...... nd phase III clinical studies.
@nl
P2093
P2860
P1433
P1476
Efficacy and safety of eslicar ...... nd phase III clinical studies.
@en
P2093
Alberto A Gabbai
António Gil-Nagel
Christian Elger
Elinor Ben-Menachem
José Lopes-Lima
Patrício Soares da-Silva
Peter Halász
Teresa Nunes
P2860
P304
P356
10.1111/J.1528-1167.2012.03605.X
P577
2012-08-06T00:00:00Z